Enlivex (ENLV) AI Stock Analysis

• Market Cap: $28.14M
• Dividend Yield: N/A
• Average Volume (3M): 106.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: 53.95%
• Country: US
• Employees: 71
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.72
• Shares Outstanding: 23,849,936
• 10 Day Avg. Volume: 115,464
• 30 Day Avg. Volume: 106,628
• PEG Ratio: -0.23
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.22
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -62.16
• Enterprise Value/Ebitda: -0.45
• 1Y Price Target: $7.00
• Price Target Upside: 498.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Enlivex's financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.

Positive Factors

Efficacy Data

Enlivex has reported positive interim efficacy data for patients in Phase 1 with significant improvements and no safety issues.

Intellectual Property

Chinese patent claims allowed for Allocetra in osteoarthritis treatment, providing added protection through at least 2040.

Negative Factors

Clinical Trial

The Phase 2 trial will rigorously evaluate joint-pain and function with a double-blind, randomized, placebo-controlled design.

Enlivex Business Overview & Revenue Model

Company Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

How the Company Makes Money

Enlivex generates revenue primarily through collaborations, partnerships, and licensing agreements related to its proprietary immunotherapy technologies. As a clinical-stage company, it does not yet have commercialized products generating direct sales revenue. Instead, its financial income is heavily reliant on funding from research grants, strategic alliances with pharmaceutical companies, and potential milestone payments or royalties from future successful commercialization of its therapies. Significant partnerships with established healthcare and pharmaceutical firms may also contribute to its earnings by providing financial support for clinical trials and research activities.

Enlivex Financial Statement Overview

Summary

Enlivex is facing challenges typical of early-stage biotechnology firms, with no revenue and ongoing losses. The firm needs to address its lack of revenue generation and improve cash flow management to ensure its financial viability. While the low debt offers some flexibility, the continuous cash burn and equity decline may limit future strategic options.

Income Statement

Enlivex has faced significant operational challenges with no reported revenue in recent periods, leading to negative gross and net margins. The consistent negative EBIT and EBITDA margins highlight ongoing profitability issues, with a lack of revenue growth exacerbating the financial strain.

Balance Sheet

The balance sheet reflects a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's equity position has weakened over time as liabilities approach total assets, reducing the equity ratio. The declining stockholders' equity is a concern for financial stability.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating operational inefficiencies and cash burn. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow from operations, posing a risk to long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	2.28M
Gross Profit	-545.00K	-835.00K	-777.00K	-546.00K	-286.00K
EBITDA	-14.47M	-28.22M	-25.02M	-18.74M	-9.50M
Net Income	-15.01M	-29.07M	-31.06M	-14.47M	-11.82M
Balance Sheet
Total Assets	27.69M	36.83M	67.64M	95.15M	40.36M
Cash, Cash Equivalents and Short-Term Investments	23.61M	27.32M	48.12M	84.13M	35.71M
Total Debt	534.00K	1.03M	4.85M	617.00K	203.00K
Total Liabilities	4.10M	6.75M	10.80M	10.11M	4.87M
Stockholders Equity	23.59M	30.08M	56.84M	85.04M	35.49M
Cash Flow
Free Cash Flow	-13.11M	-23.76M	-32.08M	-19.17M	-12.03M
Operating Cash Flow	-13.01M	-23.52M	-23.95M	-17.54M	-11.01M
Investing Cash Flow	9.06M	-25.97M	62.52M	-38.41M	-20.98M
Financing Cash Flow	6.45M	360.00K	150.00K	60.98M	33.08M

Enlivex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Positive. The current price of 1.17 is below the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.08, and above the 200-day MA of 1.14, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.00 is Neutral, neither overbought nor oversold. The STOCH value of 14.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENLV.

Enlivex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPA	54 Neutral	$77.80M	―	-121.65%	―	-0.71%	-169.29%
OVID	53 Neutral	$47.57M	―	-36.31%	―	15.73%	51.00%
PULM	53 Neutral	$21.99M	―	-93.19%	―	6.96%	32.32%
Sector *	52 Neutral	$7.61B	0.04	-62.94%	2.44%	16.14%	0.33%
ENLV	36 Underperform	$28.14M	―	-60.35%	―	―	53.95%
CVM	27 Underperform	$42.91M	―	-238.64%	―	―	30.96%
JUNS	―	$57.27M	―		―	―	―